首页> 外文期刊>Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology >ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology.
【24h】

ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology.

机译:ACCF / AHA / ASE / ASNC / HFSA / HRS / SCAI / SCCT / SCMR / STS 2013多模态合适的使用标准,用于稳定缺血性心脏病的检测和风险评估:美国心脏病基金会适当使用标准工作组的报告,美国心脏协会,美国超声心动图学会,美国核心脏病学会。

获取原文
获取原文并翻译 | 示例
           

摘要

The American College of Cardiology Foundation along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical presentations for stable ischemic heart disease (SIHD) to consider use of stress testing and anatomic diagnostic procedures. This document reflects an updating of the prior Appropriate Use Criteria (AUC) published for radionuclide imaging (RNI), stress echocardiography (Echo), calcium scoring, coronary computed tomography angiography (CCTA), stress cardiac magnetic resonance (CMR), and invasive coronary angiography for SIHD. This is in keeping with the commitment to revise and refine the AUC on a frequent basis. A major innovation in this document is the rating of tests side by side for the same indication. The side-by-side rating removes any concerns about differences in indication or interpretation stemming from prior use of separate documents for each test. However, the ratings were explicitly not competitive rankings due to the limited availability of comparative evidence, patient variability, and range of capabilities available in any given local setting. The indications for this review are limited to the detection and risk assessment of SIHD and were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Eighty clinical scenarios were developed by a writing committee and scored by a separate rating panel on a scale of 1-9, to designate Appropriate, May Be Appropriate, or Rarely Appropriate use following a modified Delphi process following the recently updated AUC development methodology. The use of some modalities of testing in the initial evaluation of patients with symptoms representing ischemic equivalents, newly diagnosed heart failure, arrhythmias, and syncope was generally found to be Appropriate or May Be Appropriate, except in cases where low pre-test probability or low risk limited the benefit of most testing except exercise electrocardiogram (ECG). Testing for the evaluation of new or worsening symptoms following a prior test or procedure was found to be Appropriate. In addition, testing was found to be Appropriate or May Be Appropriate for patients within 90 days of an abnormal or uncertain prior result. Pre-operative testing was rated Appropriate or May Be Appropriate only for patients who had poor functional capacity and were undergoing vascular or intermediate risk surgery with 1 or more clinical risk factors or an organ transplant. The exercise ECG was suggested as an Appropriate test for cardiac rehabilitation clearance or for exercise prescription purposes. Testing in asymptomatic patients was generally found to be Rarely Appropriate, except for calcium scoring and exercise testing in intermediate and high-risk individuals and either stress or anatomic imaging in higher-risk individuals, which were all rated as May Be Appropriate. All modalities of follow-up testing after a prior test or percutaneous coronary intervention (PCI) within 2 years and within 5 years after coronary artery bypass graft (CABG) in the absence of new symptoms were rated Rarely Appropriate. Pre-operative testing for patients with good functional capacity, prior normal testing within 1 year, or prior to low-risk surgery also were found to be Rarely Appropriate. Imaging for an exercise prescription or prior to the initiation of cardiac rehabilitation was Rarely Appropriate except for cardiac rehabilitation clearance for heart failure patients. Preface: In an effort to respond to the need for the rational use of imaging services in the delivery of high-quality care, the American College of Cardiology Foundation (ACCF) has undertaken a process to determine the appropriate use of cardiovascular imaging for selected patient indications. Appropriate Use Criteria (AUC) publications reflect an ongoing effort by the ACCF to critically and systematically create, review, and categorize clinical situations where tests and procedures are
机译:美国心脏病学会基金会以及主要的专业和亚专业学会对稳定的缺血性心脏病(SIHD)的常见临床表现进行了适当的使用审查,以考虑使用压力测试和解剖学诊断程序。本文档反映了先前发布的有关放射性核素成像(RNI),应力超声心动图(Echo),钙评分,冠状动脉计算机断层造影血管造影(CCTA),应力性心脏磁共振(CMR)和侵入性冠状动脉的适当使用标准(AUC)的更新。 SIHD血管造影。这符合经常修订和完善AUC的承诺。本文档中的一项重大创新是针对同一适应症的并排测试等级。并排评级消除了对由于每次测试使用单独的文档而导致的指示或解释差异的任何担忧。但是,由于比较证据的可用性有限,患者的变异性以及在任何给定的本地环境下可用的能力范围,这些评级显然不是竞争性排名。本次审查的适应症仅限于SIHD的检测和风险评估,并从常见应用或预期用途以及当前的临床实践指南中得出。一个写作委员会制定了80种临床方案,并由一个单独的评分小组以1-9的等级进行评分,以指定在按照最近更新的AUC开发方法进行改进的Delphi程序后,适当,可能适当或很少适当使用。一般认为在对代表缺血性等效物,新诊断的心力衰竭,心律不齐和晕厥的症状的患者进行初次评估时使用某些测试方法是适当的或可能是适当的,除非前测概率低或低风险限制了除运动心电图(ECG)以外的大多数测试的收益。在进行先前的测试或程序后,评估新症状或恶化症状的测试被认为是适当的。此外,对于先前结果异常或不确定的90天内的患者,发现测试是适当的或可能适当的。术前测试被评定为“适当”或“仅当”是功能不佳且正在接受具有一种或多种临床危险因素的血管或中度危险手术或器官移植的患者。建议将运动心电图作为进行心脏康复清除或运动处方目的的适当测试。一般认为,对无症状患者的测试很少,除了对中,高危人群进行钙评分和运动测试,对高危人群进行压力或解剖学影像检查均被认为是适当的。在没有新症状的情况下,在进行冠状动脉搭桥术(CABG)后2年和5年内,先验后或经皮冠状动脉介入治疗(PCI)后进行的所有随访检查的所有形式均被评定为“非常适当”。对于功能能力良好的患者,术前检查,1年以内的正常检查或低风险手术之前的检查也很少。除了对心力衰竭患者进行心脏康复检查外,对运动处方或在开始心脏康复之前进行成像非常合适。前言:为了满足在提供高质量护理时合理使用影像服务的需求,美国心脏病学会基金会(ACCF)进行了确定特定患者合理使用心血管影像的程序。适应症。适当的使用标准(AUC)出版物反映了ACCF正在进行的努力,以严格,系统地创建,审查和分类测试和程序进行的临床情况

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号